SCHEMBL3017900

SCHEMBL3017900

Cc1cccc(-c2csc(N3CCN(S(=O)(=O)c4c(C)c(C)cc(C)c4C)CC3)n2)c1C

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
LMNA P02545 3/20 0.47
MAPK1 P28482 2/20 0.47
MAPT P10636 4/20 0.46
ALDH1A1 P00352 3/20 0.46
L3MBTL1 Q9Y468 3/20 0.46
GAA P10253 1/20 0.46
HTT P42858 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
AR P10275 2/20 0.46
USP2 O75604 1/20 0.46
RECQL P46063 1/20 0.46
HSD17B10 Q99714 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
TP53 P04637 1/20 0.41
THRB P10828 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3650400 0.96 MEN1 (0.44) MEN1KMT2ALMNAMAPK1MAPT
SCHEMBL3021719 0.93 MEN1 (0.51) MEN1KMT2ALMNAMAPK1MAPT
SCHEMBL3011374 0.91 MEN1 (0.47) MEN1KMT2ALMNAMAPK1MAPT
SCHEMBL3012118 0.89 MEN1 (0.49) MEN1KMT2ALMNAMAPK1MAPT
SCHEMBL3015871 0.88 AR (0.50) MEN1KMT2ALMNAMAPK1MAPT
SCHEMBL3006465 0.88 AR (0.58) MEN1KMT2ALMNAMAPK1MAPT
SCHEMBL3652514 0.88 MAPK1 (0.60) MEN1KMT2ALMNAMAPK1MAPT
SCHEMBL3003052 0.86 MAPT (0.49) MEN1KMT2ALMNAMAPK1MAPT
SCHEMBL3016940 0.85 MEN1 (0.42) MEN1KMT2ALMNAMAPK1MAPT
SCHEMBL3013606 0.85 AR (0.61) MEN1KMT2ALMNAMAPK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MEN1 454/4885KMT2A 2680/4885LMNA 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.